EA202091095A1 - Пероральная доставка пептидных аналогов glp-1 - Google Patents

Пероральная доставка пептидных аналогов glp-1

Info

Publication number
EA202091095A1
EA202091095A1 EA202091095A EA202091095A EA202091095A1 EA 202091095 A1 EA202091095 A1 EA 202091095A1 EA 202091095 A EA202091095 A EA 202091095A EA 202091095 A EA202091095 A EA 202091095A EA 202091095 A1 EA202091095 A1 EA 202091095A1
Authority
EA
Eurasian Patent Office
Prior art keywords
glp
oral delivery
peptide analogues
formulations
methods
Prior art date
Application number
EA202091095A
Other languages
English (en)
Inventor
Сергей Печенов
Пунит Тйаги
Джанардханан Ананд Субрамони
Original Assignee
Медиммун Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиммун Лимитед filed Critical Медиммун Лимитед
Publication of EA202091095A1 publication Critical patent/EA202091095A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

В настоящем изобретении предусмотрены составы для перорального введения пептидных аналогов GLP-1, способы получения таких составов и способы лечения с помощью таких составов.
EA202091095A 2017-10-31 2018-10-30 Пероральная доставка пептидных аналогов glp-1 EA202091095A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762579186P 2017-10-31 2017-10-31
PCT/IB2018/058514 WO2019087083A2 (en) 2017-10-31 2018-10-30 Oral delivery of glp-1 peptide analogs

Publications (1)

Publication Number Publication Date
EA202091095A1 true EA202091095A1 (ru) 2020-09-18

Family

ID=66331379

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091095A EA202091095A1 (ru) 2017-10-31 2018-10-30 Пероральная доставка пептидных аналогов glp-1

Country Status (23)

Country Link
US (1) US11173124B2 (ru)
EP (1) EP3703817A4 (ru)
JP (1) JP2021501172A (ru)
KR (1) KR20200081411A (ru)
CN (1) CN111655338A (ru)
AR (1) AR116451A1 (ru)
AU (1) AU2018360382A1 (ru)
BR (1) BR112020008220A2 (ru)
CA (1) CA3079376A1 (ru)
CL (1) CL2020001131A1 (ru)
CO (1) CO2020005485A2 (ru)
CR (1) CR20200185A (ru)
DO (1) DOP2020000082A (ru)
EA (1) EA202091095A1 (ru)
IL (1) IL274096A (ru)
MA (1) MA50047A (ru)
MX (1) MX2020004497A (ru)
PE (1) PE20210116A1 (ru)
PH (1) PH12020551018A1 (ru)
SG (1) SG11202003627PA (ru)
TW (1) TW201932139A (ru)
WO (1) WO2019087083A2 (ru)
ZA (1) ZA202003149B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202091095A1 (ru) * 2017-10-31 2020-09-18 Медиммун Лимитед Пероральная доставка пептидных аналогов glp-1
FR3120189A1 (fr) * 2021-03-01 2022-09-02 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1
KR20230010571A (ko) 2021-07-12 2023-01-19 한미약품 주식회사 Glp-1 유사체를 함유하는 경구 투여 제형 조성물
WO2023065231A1 (en) * 2021-10-21 2023-04-27 Guangzhou Dazhou Biomedicine Ltd. Oral delivery of therapeutic agents
WO2023161792A1 (en) * 2022-02-22 2023-08-31 Astrazeneca Ab Compressible sodium caprate formulations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5556837A (en) * 1994-08-01 1996-09-17 Regeneron Pharmaceuticals Inc. Methods for treating addictive disorders
GB0308734D0 (en) 2003-04-15 2003-05-21 Axcess Ltd Uptake of macromolecules
EP2679270B1 (en) 2011-02-24 2016-11-09 Hisamitsu Pharmaceutical Co., Inc. Glp-1 analogue composition for microneedle devices
US20150133373A1 (en) * 2012-03-28 2015-05-14 Amylin Pharmaceuticals, Llc Transmucosal delivery of engineered polypeptides
RU2671406C2 (ru) * 2013-05-02 2018-10-31 Ново Нордиск А/С Пероральная дозированная форма соединений глюкагоноподобного пептида-1
JP2016524617A (ja) 2013-05-30 2016-08-18 ノヴォ ノルディスク アー／エス 糖尿病の治療のための新規な経口医薬組成物
TWI726889B (zh) * 2015-06-10 2021-05-11 英商梅迪繆思有限公司 蛋白酶抗性之脂化肽
CN106366166A (zh) * 2016-08-30 2017-02-01 苏州普罗达生物科技有限公司 脑源性神经营养因子促进剂多肽及应用
EA202091095A1 (ru) 2017-10-31 2020-09-18 Медиммун Лимитед Пероральная доставка пептидных аналогов glp-1

Also Published As

Publication number Publication date
AU2018360382A1 (en) 2020-06-18
WO2019087083A2 (en) 2019-05-09
US11173124B2 (en) 2021-11-16
PH12020551018A1 (en) 2021-05-31
JP2021501172A (ja) 2021-01-14
MA50047A (fr) 2020-07-08
CA3079376A1 (en) 2019-05-09
CO2020005485A2 (es) 2020-05-15
WO2019087083A3 (en) 2019-08-08
CR20200185A (es) 2020-06-19
DOP2020000082A (es) 2020-08-31
KR20200081411A (ko) 2020-07-07
PE20210116A1 (es) 2021-01-19
EP3703817A4 (en) 2021-08-18
IL274096A (en) 2020-06-30
BR112020008220A2 (pt) 2020-10-27
EP3703817A2 (en) 2020-09-09
ZA202003149B (en) 2021-06-30
TW201932139A (zh) 2019-08-16
SG11202003627PA (en) 2020-05-28
US20200323782A1 (en) 2020-10-15
CL2020001131A1 (es) 2020-10-23
CN111655338A (zh) 2020-09-11
AR116451A1 (es) 2021-05-12
MX2020004497A (es) 2020-08-13

Similar Documents

Publication Publication Date Title
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
PH12021551065A1 (en) Fused ring compounds
MX2022001755A (es) Compuestos de dinucleotidos ciclicos y metodos de uso.
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
PH12020550051A1 (en) Glp-1 compositions and uses thereof
MX2022015257A (es) Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
CY1122716T1 (el) Ρινικη συσταση κονεως για την αγωγη της υπογλυκαιμιας
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
EA201890068A1 (ru) Частицы диметилфумарата и фармацевтические композиции на их основе
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
EA202190057A1 (ru) Солюбилизированные апиразы, способы и применение
EA202090705A1 (ru) Способы и композиции, предназначенные для лечения хронических заболеваний легких
PH12020551618A1 (en) Erenumab compositions and uses thereof
EA201690732A1 (ru) Агонисты гуанилатциклазы, используемые для лечения индуцированных опиоидами дисфункций
MX2021005910A (es) Formulacion de proteina de alta concentracion.
EA201892837A1 (ru) Физиологически сбалансированные составы для инъекций, включающие фоснетупитант
EA202290107A1 (ru) Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1
EA202090971A1 (ru) Способы применения и композиции, содержащие дулаглутид
EA202191327A1 (ru) Лекарственные формы терапевтических препаратов от гриппа
EA202192475A1 (ru) Способ получения стабильных пептидных составов
EA201892095A1 (ru) Циклические динуклеотидные соединения и способы их применения